BMS MULTICENTER ARIPIPRAZOLE DLW STUDY

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This project aims to quantify treatment-induced changes in Total Energy Expenditure (TEE), Activity Energy Expenditure (AEE), and Energy Intake (ET) in schizophrenia patients during twelve weeks of prospective, randomized treatment with either olanzapine or ziprasidone. This project will provide for DLW measurements in a subject of the olanzapine- and ziprasidone-treated subjects in an ongoing larger R01-funded study of the metabolic effects of four different antipsychotic agents (PI: Newcomer, MH #063985-05, GCRC approved protocol: 811.2). Olanzapine and ziprasidone treated subjects are selected for DLW measurements based on the prominent weight gain effects of olanzapine and the minimal effects of ziprasidone, in order to obtain pilot data on the use of this methodology to assess the effects of antipsychotics on caloric intake and activity level.